Last reviewed · How we verify

Propofol, Midazolam, and Fentanyl

Montefiore Medical Center · FDA-approved active Small molecule

This is a combination of three sedative and analgesic agents that work together to produce anesthesia, sedation, and pain relief through different mechanisms at the central nervous system.

This is a combination of three sedative and analgesic agents that work together to produce anesthesia, sedation, and pain relief through different mechanisms at the central nervous system. Used for Induction and maintenance of general anesthesia, Sedation in intensive care units, Procedural sedation.

At a glance

Generic namePropofol, Midazolam, and Fentanyl
Also known asDiprivan
SponsorMontefiore Medical Center
Drug classSedative-hypnotic/opioid combination
TargetGABA-A receptor (propofol, midazolam); mu-opioid receptor (fentanyl)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Propofol is a GABA-A receptor agonist that produces sedation and hypnosis. Midazolam is a benzodiazepine that enhances GABA-A receptor activity to provide anxiolysis and sedation. Fentanyl is an opioid mu-receptor agonist that provides analgesia and potentiates sedation. Together, they create balanced anesthesia with sedation, analgesia, and amnesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: